Harvala H - Search Results

1

Changes in transmission of Enterovirus D68 (EV-D68) in England inferred from seroprevalence data.

Pons-Salort M, Lambert B, Kamau E, Pebody R, Harvala H, Simmonds P, Grassly NC. Pons-Salort M, et al. Among authors: harvala h. Elife. 2023 Jun 9;12:e76609. doi: 10.7554/eLife.76609. Elife. 2023. PMID: 37294299 Free PMC article.

2

Cryptosporidium infections in Sweden-understanding the regional differences in reported incidence.

Harvala H, Ögren J, Boman P, Riedel HM, Nilsson P, Winiecka-Krusnell J, Beser J. Harvala H, et al. Clin Microbiol Infect. 2016 Dec;22(12):1012-1013. doi: 10.1016/j.cmi.2016.09.012. Epub 2016 Sep 23. Clin Microbiol Infect. 2016. PMID: 27665706 Free article. No abstract available.

3

Emergence and spread of moxifloxacin-resistant Clostridium difficile ribotype 231 in Sweden between 2006 and 2015.

Harvala H, Alm E, Åkerlund T, Rizzardi K. Harvala H, et al. New Microbes New Infect. 2016 Sep 16;14:58-66. doi: 10.1016/j.nmni.2016.09.002. eCollection 2016 Nov. New Microbes New Infect. 2016. PMID: 27752322 Free PMC article.

4

Evaluation of the national laboratory-based surveillance system for respiratory syncytial virus in Sweden, 2015-2016.

Harvala H, Carnahan A, Axelsson S, Brytting M. Harvala H, et al. J Clin Virol. 2018 Jul;104:11-15. doi: 10.1016/j.jcv.2018.04.004. Epub 2018 Apr 10. J Clin Virol. 2018. PMID: 29704733

5

Molecular epidemiology and evolution of coxsackievirus A9.

Santti J, Harvala H, Kinnunen L, Hyypiä T. Santti J, et al. Among authors: harvala h. J Gen Virol. 2000 May;81(Pt 5):1361-72. doi: 10.1099/0022-1317-81-5-1361. J Gen Virol. 2000. PMID: 10769080

6

Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary.

Wouters E, Steenhuis M, Schrezenmeier H, Tiberghien P, Harvala H, Feys HB, van der Schoot E. Wouters E, et al. Among authors: harvala h. Vox Sang. 2021 May;116(5):493-496. doi: 10.1111/vox.13060. Epub 2020 Dec 23. Vox Sang. 2021. PMID: 33368373 Free PMC article. No abstract available.

7

The need for treatment against human parechoviruses: how, why and when?

Wildenbeest JG, Harvala H, Pajkrt D, Wolthers KC. Wildenbeest JG, et al. Among authors: harvala h. Expert Rev Anti Infect Ther. 2010 Dec;8(12):1417-29. doi: 10.1586/eri.10.130. Expert Rev Anti Infect Ther. 2010. PMID: 21133666 Review.

8

Tissue tropism of recombinant coxsackieviruses in an adult mouse model.

Harvala H, Kalimo H, Bergelson J, Stanway G, Hyypiä T. Harvala H, et al. J Gen Virol. 2005 Jul;86(Pt 7):1897-1907. doi: 10.1099/vir.0.80603-0. J Gen Virol. 2005. PMID: 15958668

9

Epidemiology of Campylobacter jejuni infections in Sweden, November 2011-October 2012: is the severity of infection associated with C. jejuni sequence type?

Harvala H, Rosendal T, Lahti E, Engvall EO, Brytting M, Wallensten A, Lindberg A. Harvala H, et al. Infect Ecol Epidemiol. 2016 Apr 7;6:31079. doi: 10.3402/iee.v6.31079. eCollection 2016. Infect Ecol Epidemiol. 2016. PMID: 27059819 Free PMC article.

10

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison.

National SARS-CoV-2 Serology Assay Evaluation Group. National SARS-CoV-2 Serology Assay Evaluation Group. Lancet Infect Dis. 2020 Dec;20(12):1390-1400. doi: 10.1016/S1473-3099(20)30634-4. Epub 2020 Sep 23. Lancet Infect Dis. 2020. PMID: 32979318 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

133 results

Search Page

Filters